Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 3/20 | 0.74 |
| ▸ | MAPT | P10636 | 6/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 4/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24878305 | 1.00 | IDO1 (0.74) | IDO1MAPTALDH1A1KDM4EALOX15 | |
| SCHEMBL24878143 | 1.00 | IDO1 (0.74) | IDO1MAPTALDH1A1KDM4EALOX15 | |
| SCHEMBL30129189 | 1.00 | IDO1 (0.74) | IDO1MAPTALDH1A1KDM4EALOX15 | |
| SCHEMBL24878684 | 0.93 | IDO1 (0.65) | IDO1MAPTALDH1A1KDM4EALOX15 | |
| SCHEMBL24878019 | 0.92 | IDO1 (0.70) | IDO1MAPTALDH1A1KDM4EALOX15 | |
| SCHEMBL24878473 | 0.92 | IDO1 (0.75) | IDO1MAPTALDH1A1KDM4EALOX15 | |
| SCHEMBL24878620 | 0.91 | IDO1 (0.72) | IDO1MAPTALDH1A1KDM4EALOX15 | |
| SCHEMBL24878702 | 0.91 | IDO1 (0.69) | IDO1MAPTALDH1A1KDM4EALOX15 | |
| SCHEMBL24878724 | 0.91 | IDO1 (0.79) | IDO1MAPTALDH1A1KDM4EALOX15 | |
| SCHEMBL30128819 | 0.91 | IDO1 (0.79) | IDO1MAPTALDH1A1KDM4EALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3886845-B1 | NOVEL SUBSTITUTED PIPERAZINE AMIDE COMPOUNDS AS INDOLEAMINE 2, 3-DIOXYGENASE (IDO) INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2024-09-04 | — | — | EP | claimed |
| US-12264134-B2 | Substituted piperazine amide compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors | MERCK SHARP & DOHME LLC (US) | 2025-04-01 | — | — | US | disclosed |
| EP-3886845-B1 | NOVEL SUBSTITUTED PIPERAZINE AMIDE COMPOUNDS AS INDOLEAMINE 2, 3-DIOXYGENASE (IDO) INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2024-09-04 | — | — | EP | disclosed |
| US-20230008022-A1 | NOVEL SUBSTITUTED PIPERAZINE AMIDE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2023-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230008022-A1 | NOVEL SUBSTITUTED PIPERAZINE AMIDE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | IDO1, IDO2, KYNU | IDO1 1/4885MAPT 2271/4885ALDH1A1 328/4885 |
| US-12264134-B2 | Substituted piperazine amide compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors | IDO1, IDO2, AADAC | IDO1 1/4885MAPT 2376/4885ALDH1A1 325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.